A Retrospective Chart Review Study of Patients With CLAD-BOS Post Lung Transplantation
Public ClinicalTrials.gov record NCT06503770. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Retrospective Chart Review Study of Patients With Chronic Lung Allograft Dysfunction-Bronchiolitis Obliterans Syndrome (CLAD-BOS) Post Lung Transplantation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The Primary Objective of this study was to evaluate the FEV1 trajectory of patients diagnosed with CLAD-BOS. The Secondary Objectives of this study were: * To describe demographics of patients diagnosed with CLAD-BOS * To describe clinical characteristics following lung transplantation for patients diagnosed with CLAD-BOS * To evaluate the trajectory of other relevant spirometry parameters (ie, FVC, FEV1/FVC, FEF25-75%) * To evaluate the OS of patients diagnosed with CLAD-BOS * To evaluate the time to first CLAD-BOS progression * To evaluate the cumulative incidence of CLAD-BOS progression * To evaluate the rate of hospitalization due to respiratory failure after CLAD-BOS onset * To evaluate the incidence of concomitant respiratory disease * To evaluate the incidence of concomitant non-respiratory disease * To describe the use of concomitant treatments and procedures for CLAD-BOS.
Study identification
- NCT ID
- NCT06503770
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 284 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 26, 2024
- Primary completion
- Apr 8, 2025
- Completion
- Apr 8, 2025
- Last update posted
- Aug 31, 2026
2024 – 2025
United States locations
- U.S. sites
- 3
- U.S. states
- 2
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cleveland Clinic Transplantation Center | Cleveland | Ohio | 44195 | — |
| The Ohio State University | Columbus | Ohio | 43210 | — |
| Baylor Scott and White Health Center for Advanced Heart and Lung Disease | Dallas | Texas | 75246 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06503770, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 31, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06503770 live on ClinicalTrials.gov.